HSF1 and prostate cancer: The studies herein demonstrate that NXP800 reduced basal and HSF1-mediated, HSP90 inhibitor–induced, HSP72 protein expression levels in prostate cancer cell lines, consistent with its mechanistic development rationale and preclinical therapeutic activity in sensitive preclinical models of ovarian cancer (40, 70).